タジマ　ヒロユキ   TAJIMA Hiroyuki   田島　廣之    所属   埼玉医科大学  医学部 国際医療センター　放射線科（放射線腫瘍科、画像診断、核医学科）    職種   特任教授
論文種別	学術雑誌(原著)
言語種別	英語
査読の有無	査読あり
表題	Oily chemoembolization combined with degradable starch microspheres for HCC with cirrhosis
掲載誌名	正式名：HEPATO-GASTROENTEROLOGY ISSNコード：01726390
出版社	H G E UPDATE MEDICAL PUBLISHING S A
巻・号・頁	55(84),1041-1046頁
著者・共著者	Satoru Murata,Hiroyuki Tajima,Kazuo Ichikawa,Shiro Onozawa,Jian Wang,Shinichiro Kumita,Kazuhiro Nomura
発行年月	2008/05
概要	Background/Aims: To assess efficacy of transcatheter arterial chemoembolization (TACE) combined with degradable starch microspheres (DSM) forpatients with liver cirrhosis and hepatocellular carcinoma (HCC).Methodology: Our studied population was 19 patients with unresectable HCC and liver dysfunction due to repeated TACE, in whom we were unable to selectively advance a microcatheter into the feeding arteries because of tortuous or complex feeding arteries to the HCC. To avoid embolization of an extended non-tumorous area, we conducted Lipiodol-TACE after DSM-embolization (TACE-DSM) of the tumor-free parenchyma. Embolization data and clinical parameters were prospectively assessed.Results: TACE-DSM was performed 21 times in the 19 patients, and the overall technical success rate was 81%. The TACE-DSM method did not induce severe liver dysfunction. A favorable response involving necrosis of more than 80% or 50% of the tumor was seen in 62% and 90% of cases, respectively. In the follow-up period (8 to 36 months), complete necrosis of the targeted tumors was observed in 26% of cases. The 2-year survival rates calculated as starting from the date of TACE-DSM therapy was 32.6%.Conclu